Summit Therapeutics Price Targets Cut After FDA Rejection: What Analysts Said About SMMT
Evercore ISI and Barclays kept their ratings on Summit but lowered price targets after the FDA declined ivonescimab. Shares closed Nov. 16 at $11.82, down 16.47% from the Nov. 13 close.



